Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
39 hedge funds and large institutions have $10.6M invested in Oncternal Therapeutics, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
3% more funds holding
Funds holding: 38 → 39 (+1)
5% less capital invested
Capital invested by funds: $11.2M → $10.6M (-$595K)
93% less call options, than puts
Call options by funds: $2K | Put options by funds: $28K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$369K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$70K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$21.1K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$13.2K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$7.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$42.3K |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$29K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$7.93K |
| 5 |
HCMT
Highland Capital Management (Tennessee)
Memphis,
Tennessee
|
-$2.64K |
ONCT Hedge Fund Activity: Q4 2015 in Review
39 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2015, worth a combined $10.6M — down 5.3% from $11.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ONCT positions and 2 closed out — a net gain of 2 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was BVF Inc, adding an estimated $369K. The largest seller was Morgan Stanley, cutting an estimated $42.3K.
- 39 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2015, up from 38 in Q3 2015.
- Funds reported $10.6M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2015, down 5.3% quarter-over-quarter.
- 4 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2015 and 2 closed out, a net change of +2 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2015 was BVF Inc, an estimated $369K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2015 was Morgan Stanley, an estimated $42.3K sold.
Based on aggregated 13F filings for Q4 2015.